Literature DB >> 24920209

Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.

E Saussereau1, I Vachier, R Chiron, B Godbert, I Sermet, N Dufour, J-P Pirnay, D De Vos, F Carrié, N Molinari, L Debarbieux.   

Abstract

Bacteriophages have been shown to be effective for treating acute infections of the respiratory tract caused by antibiotic-resistant bacteria in animal models, but no evidence has yet been presented of their activity against pathogens in complex biological samples from chronically infected patients. We assessed the efficacy of a cocktail of ten bacteriophages infecting Pseudomonas aeruginosa following its addition to 58 sputum samples from cystic fibrosis (CF) patients collected at three different hospitals. Ten samples that did not contain P. aeruginosa were not analysed further. In the remaining 48 samples, the addition of bacteriophages led to a significant decrease in the levels of P. aeruginosa strains, as shown by comparison with controls, taking two variables (time and bacteriophages) into account (p = 0.024). In 45.8% of these samples, this decrease was accompanied by an increase in the number of bacteriophages. We also tested each of the ten bacteriophages individually against 20 colonies from each of these 48 samples and detected bacteriophage-susceptible bacteria in 64.6% of the samples. An analysis of the clinical data revealed no correlation between patient age, sex, duration of P. aeruginosa colonization, antibiotic treatment, FEV1 (forced expiratory volume in the first second) and the efficacy of bacteriophages. The demonstration that bacteriophages infect their bacterial hosts in the sputum environment, regardless of the clinical characteristics of the patients, represents a major step towards the development of bacteriophage therapy to treat chronic lung infections.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Chronic infection; Pseudomonas aeruginosa; phage therapy; pulmonary infection

Mesh:

Year:  2014        PMID: 24920209     DOI: 10.1111/1469-0691.12712

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  21 in total

Review 1.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

2.  The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence.

Authors:  Zachary J Storms; Matthew R Teel; Kevin Mercurio; Dominic Sauvageau
Journal:  Phage (New Rochelle)       Date:  2020-02-25

3.  Effect of storage temperature on the stability of spray dried bacteriophage powders.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; An Nguyen; Thomas Gengenbach; Elizabeth A Carter; Nicholas B Carrigy; Hui Wang; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2018-02-24       Impact factor: 5.571

4.  The search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae.

Authors:  Marine Henry; Louis-Marie Bobay; Anne Chevallereau; Emilie Saussereau; Pieter-Jan Ceyssens; Laurent Debarbieux
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

Review 5.  Phage therapy of pulmonary infections.

Authors:  Stephen T Abedon
Journal:  Bacteriophage       Date:  2015-04-18

Review 6.  Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics.

Authors:  Callum J Cooper; Mohammadali Khan Mirzaei; Anders S Nilsson
Journal:  Front Microbiol       Date:  2016-08-03       Impact factor: 5.640

Review 7.  The Microbiome in Cystic Fibrosis.

Authors:  Yvonne J Huang; John J LiPuma
Journal:  Clin Chest Med       Date:  2015-12-23       Impact factor: 2.878

8.  The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage.

Authors:  Bartosz Roszniowski; Agnieszka Latka; Barbara Maciejewska; Dieter Vandenheuvel; Tomasz Olszak; Yves Briers; Giles S Holt; Miguel A Valvano; Rob Lavigne; Darren L Smith; Zuzanna Drulis-Kawa
Journal:  Appl Microbiol Biotechnol       Date:  2016-10-21       Impact factor: 4.813

9.  A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections.

Authors:  Katarzyna Danis-Wlodarczyk; Dieter Vandenheuvel; Ho Bin Jang; Yves Briers; Tomasz Olszak; Michal Arabski; Slawomir Wasik; Marcin Drabik; Gerard Higgins; Jean Tyrrell; Brian J Harvey; Jean-Paul Noben; Rob Lavigne; Zuzanna Drulis-Kawa
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

Review 10.  Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status.

Authors:  Sami Hraiech; Fabienne Brégeon; Jean-Marc Rolain
Journal:  Drug Des Devel Ther       Date:  2015-07-16       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.